People
Treanor Named President of Relypsa and Member of the Executive Committee of Vifor Pharma Group
13 December 2018 - - Switzerland-based pharmaceuticals company Vifor Pharma Group has appointed Patrick Treanor as president of Relypsa on a permanent basis, the company said.

He is also appointed to the executive committee of Vifor Pharma Group with immediate effect.

Treanor was appointed interim president of Relypsa, the US affiliate of Vifor Pharma Group on 20 September 2018.

He joined Relypsa in 2015 to establish the sales organisation for the US launch of Veltassa.

In April 2017, he was appointed senior vice president and chief commercial officer of Relypsa and has been instrumental in leading the commercialisation strategy of Veltassa and driving Relypsa to achieve its goal of becoming a leader in nephrology and cardio-renal therapies.

Vifor Pharma Group is a global pharmaceuticals company. It aims to become a leader in iron deficiency, nephrology and cardio-renal therapies.

The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.

Vifor Pharma develops, manufactures and markets pharmaceutical products for precision patient care.

The company holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma.

Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

Relypsa, Inc., a Vifor Pharma Group company, is a biopharmaceutical company focused on the development and commercialization of late-stage medicines in the iron deficiency, nephrology and cardio-renal therapeutic areas.

Relypsa is committed to delivering innovative therapies and improving the lives of patients with serious and life-threatening conditions that are often overlooked and undertreated.

The company's first medicine, Veltassa (patiromer) for oral suspension, was approved by the US FDA in October 2015, making it the first approved medicine for the treatment of hyperkalaemia in more than 50 years.

Veltassa is a sodium-free potassium binder approved for the treatment of hyperkalaemia. Veltassa should not be used as an emergency treatment for life-threatening hyperkalaemia because of its delayed onset of action.

Made in powder form consisting of smooth, spherical beads, Veltassa is mixed with water (one-third of a cup) and taken once-a-day. Veltassa is not absorbed and acts within the gastrointestinal tract. It binds to potassium in exchange for calcium, primarily in the colon.

The potassium is then excreted from the body through the normal excretion process.

Veltassa is contraindicated in patients with a history of a hypersensitivity reaction to Veltassa or any of its components.

Use of Veltassa should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because Veltassa may be ineffective and may worsen gastrointestinal conditions.

Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Veltassa binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with Veltassa.

Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value
Login
Username:

Password: